Eurasian Medical Journal

International Higher School of Medicine

ISSN 1694-8254


R. B. Sultanalieva1, V. G. Knyazeva1, K. B. Jooshbaev2, D. M. Satarova2, N. N. Usubaliev1.

Angiotensin-converting enzyme (ACE) inhibitors and type 1 angiotensin receptor blockers (ARBS) can slow the progression of nephropathy and provide regression of albuminuria and proteinuria in diabetes mellitus (DM). Effective reduction of blood pressure in patients with DM is no less significant for reducing the risk of complications than careful control of glycemia. Achieving the target blood pressure (BP) is one of the strategies for preventing cardiovascular complications in patients with diabetes.
This study aimed to evaluate the effectiveness and safety of Rotazar in patients with type 2 diabetes mellitus with uncontrolled arterial hypertension. Twenty patients (16 women and 4 men) were treated with Rotazar for 12 weeks with a diagnosis of diabetes and hypertension with no achievement of target blood pressure values. The drug was recommended to be taken 1 time a day in the morning at a dose of 150 mg. If the target blood pressure was not reached in one patient at the visit after 4 weeks, the dose was increased to 300 mg, 3 people were transferred to Rotazar plus (irbesartan 150 mg, hydrochlorothiazide 12.5 mg). It was found that all patients with grade 1 hypertension achieved the target blood pressure values (100%) during Rotazar monotherapy, while patients with grade 2-3 hypertension who received combined therapy with Rotazar achieved the target blood pressure level in 78.6%. In total, the positive dynamics of blood pressure was detected in 85% of the patients we observed. No patient's blood pressure decreased to less than 120/80 mmHg. It was concluded that the therapeutic regimen with the use of Rotazar as a monotherapy and in combination with other drugs in patients with type 2 diabetes with uncontrolled hypertension 1-2-3rd  degree shows a high antihypertensive efficacy, allowing you to reach target values of BP in 85% of patients after 12‑week treatment with the satisfactory safety profile and metabolic neutrality.
Keywords: diabetes mellitus and hypertension, the selective receptor antagonists of angiotensin-II (type ATII), Rotazar.